Niagen Bioscience (NAGE) announced the broadening of its NAD+ precursor intellectual property portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside and derivatives in intravenous and injectable formulations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE: